Skip to main content
. 2024 Mar 15;13:1297497. doi: 10.3389/fonc.2023.1297497

Table 2.

The comparison of baseline characteristics of all patients by group.

Variables Classification low-risk groups (n= 155) n (%) high-risk groups (n=53) n (%) P-value
Gender Female
Male
129(83.226)
26(16.774)
48(90.566)
5(9.434)
0.195
Age (years) <25
≥25
50(32.258)
105(67.742)
24(45.283)
29(54.717)
0.087
Symptomatic -
+
84(54. 194)
71(45.806)
7(13.208)
46(86.792)
<0.001
The maximum diameter (cm) <7.2
≥7.2
109(70.323)
46(29.677)
21(39.623)
32(60.377)
<0.001
Location Head
Neck
Body
Tail
36(23.226)
19(12.258)
39(25. 161)
61(39.355)
10(18.868)
12(22.642)
8(15.094)
23(43.396)
0.163
Margin Clear
Not Clear
98(63.226)
57(36.774)
15(28.302)
38(71.698)
<0.001
Calcification -
+
61(39.355)
94(60.645)
16(30. 189)
37(69.811)
0.233
Capsule Complete
Incomplete
102(65.806)
53(34. 194)
15(28.302)
38(71.698)
<0.001
Distal pancreatic atrophy No
Yes
110(70.968)
45(29.032)
45(84.906)
8(15.094)
0.044
Pancreatic and bile duct dilation No
Yes
116(74.839)
39(25. 161)
36(67.925)
17(32.075)
0.327
Tumor markers -
+
139(89.677)
16(10.323)
44(83.019)
9(16.981)
0.198
Viral hepatitis -
+
149(96. 129)
6(3.871)
48(90.566)
5(9.434)
0.118
NLR <1.54
≥1.54
63(40.645)
92(59.355)
15(28.302)
38(71.698)
0.109
PLR <117.7
≥117.7
50(32.258)
105(67.742)
24(45.283)
29(54.717)
0.087
SII <781.44
≥781.44
129(83.226)
26(16.774)
38(71.698)
15(28.302)
0.069
PNI <47.45
≥47.45
24(15.484)
131(84.516)
22(41.509)
31(58.491)
<0.001
LMR <5.519
≥5.519
86(55.484)
69(44.516)
38(71.698)
15(28.302)
0.038
SIRI <5.23
≥5.23
127(81.935)
28(18.065)
35(66.038)
18(33.962)
0.016
ki67, n (%) ≤3%
3-5%
≥5%
130(83.871)
12(7.742)
13(8.387)
40(75.472)
7(13.208)
6(11.321)
0.367

+, yes; −, no; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; LMR, lymphocyte-to-monocyte ratio; SIRI, systemic inflammatory response index; PNI, prognostic nutritional index.